إسرائيل - العبرية - Ministry of Health

novartis pharma services ag - mycophenolic acid 180 mg - film coated tablets - mycophenolic acid - myfortic is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants.

إسرائيل - العبرية - Ministry of Health

novartis pharma services ag - mycophenolic acid 360 mg - film coated tablets - mycophenolic acid - myfortic is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants.

إسرائيل - العبرية - Ministry of Health

novartis pharma services ag - everolimus 0.1 mg - tablets dispersible - everolimus - kidney and heart transplantationcertican® is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. in kidney and heart transplantation, certican should be used in combination with ciclosporin for microemulsion and corticosteroids.liver transplantationcertican is indicated for the prophylaxis of organ rejection in patients receiving a hepatic transplant. in liver transplantation, certican should be used in combination with tacrolimus and corticosteroids.

إسرائيل - العبرية - Ministry of Health

novartis pharma services ag - everolimus 0.25 mg - tablets dispersible - everolimus - kidney and heart transplantationcertican® is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant. in kidney and heart transplantation, certican should be used in combination with ciclosporin for microemulsion and corticosteroids.liver transplantationcertican is indicated for the prophylaxis of organ rejection in patients receiving a hepatic transplant. in liver transplantation, certican should be used in combination with tacrolimus and corticosteroids.

إسرائيل - العبرية - Ministry of Health

novartis pharma services ag - diclofenac sodium 100 mg - tablets slow release - diclofenac - anti-rheumatic, anti-inflammatory, analgesic.

إسرائيل - العبرية - Ministry of Health

novartis pharma services ag - diclofenac sodium 50 mg - suppositories - diclofenac - anti-rheumatic, anti-inflammatory, analgesic

إسرائيل - العبرية - Ministry of Health

novartis pharma services ag - diclofenac sodium 75 mg / 3 ml - solution for injection - diclofenac - intramuscular injectiontreatment of: - exacerbations of inflammatory and degenerative forms of rheumatism: rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, spondylarthritis, non-articular rheumatism.- treatment of painful conditions due to inflammation of non rheumatic origin.- renal colic and biliary colic - post-traumatic and post-operative pain, inflammation and swelling

إسرائيل - العبرية - Ministry of Health

novartis pharma services ag - pamidronate disodium 30 mg/vial - powder for solution for infusion - pamidronic acid - treatment of: tumor induced hypercalcaemia, bone metastases and multiple myeloma. for the treatment of paget's disease of bone.

إسرائيل - العبرية - Ministry of Health

novartis pharma services ag - zoledronic acid 4 mg/vial - powder for solution for infusion - zoledronic acid - treatment of hypercalcaemia of malignancy. treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. prostate cancer should have progressed after treatment with at least one hormonal therapy.

إسرائيل - العبرية - Ministry of Health

novartis pharma services ag - zoledronic acid 4 mg/vial - concentrate for solution for infusion - zoledronic acid - treatment of hypercalcaemia of malignancy. treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors , in conjunction with standard antineoplastic therapy. prostate cancer should have progressed after treatment with at least one hormonal therapy.